What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2284
https://www.valueinhealthjournal.com/article/S1098-3015(14)04214-4/fulltext
Title :
What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04214-4&doi=10.1016/j.jval.2014.08.2284
First page :
A636
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1742